Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 April 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Renal cell carcinoma Pathways Pilot [ID6186]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC